Presented during Myotonic’s Friday Afternoon Webinar Series.
This presentation will discuss the outcome of the recent study exploring the prevalence of myotonic dystrophy type 1 in the United States. We will discuss the study, the first of its kind focused on myotonic dystrophy, including how common we now believe the disease to be in the general population, how that number as determined, implications for ongoing testing for DM1 in the general population, and what it may mean for helping advance DM1 treatment and drug development.
About the Presenter: Dr. Nicholas Johnson treats adults and children with both common and rare neuromuscular conditions, yet his work doesn’t end in the clinic. He dedicates significant time each week to laboratory research, and is part of a team at VCU Health working to advance the treatment of genetic muscle disorders, with a special emphasis on muscular dystrophies. Dr. Johnson is board-certified in neurology, neuromuscular medicine and neuromuscular pathology by the American Academy of Neurology, and serves on its government relations committee.
